QL1604 + bevacizumab

QL1604 + bevacizumab is a **combination therapy** consisting of QL1604, a novel monoclonal antibody targeting the programmed cell death protein 1 (PD-1) checkpoint, and bevacizumab, a well-established monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis[1]. QL1604 is an immune checkpoint inhibitor that enhances anti-tumor immune activity by blocking PD-1, restoring T-cell function, and enabling immune-mediated tumor cell killing. Bevacizumab inhibits angiogenesis and tumor growth by binding VEGF-A, preventing its interaction with receptors VEGFR-1 and VEGFR-2 on endothelial cells, thus depriving tumors of nutrients via reduced blood vessel formation[1][2][7][6]. This combination is being studied primarily as a potential first-line therapy for advanced hepatocellular carcinoma (HCC), particularly in patients with intraspinal and metastatic disease[1]. The therapy is investigational, with QL1604 currently unmarketed and in clinical development.

Brand names

QL1604 + bevacizumab

Other names

QL1604 plus bevacizumabQL-1604 plus bevacizumabQL 1604 plus bevacizumabQL-1604 + bevacizumab